Special Offers & Promotions



Latest News



View Channel

New Products



View Channel

Video Presentations



View Channel

Separation Science



View Channel

Microscopy & Image Analysis



View Channel

Laboratory Automation & IT Solutions



View Channel


PhoreMost expands into new facility at Unity Campus, Cambridge, UK

publication date: Feb 4, 2022
author/source: PhoreMost


New state-of-the-art facility has been designed to support PhoreMost’s phenotypic screening expertise

PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, today announced it has relocated its headquarters to Unity Campus, a high-specification technology and innovation park, owned by leading regional property developers and investors, Howard Group, in south Cambridge.

Designed to support PhoreMost’s phenotypic screening requirements and expertise, the new bespoke 14,900 sq ft state-of-the-art facility is split equally between office and laboratory space, with an additional 4,000 sq ft of warehouse storage. The space, within The Works, Unity Campus’ latest combined office and R&D building, enables the Company to add in-house flow cytometry and imaging capabilities. Nearly doubling the size of its previous facilities, the relocation accommodates PhoreMost’s accelerated expansion and ongoing recruitment efforts within one location, including the recent appointment of Dr Christian Dillon as Chief Scientific Officer.

Based within the South Cambridge Science Cluster, PhoreMost’s relocation to Unity Campus places the Company in close proximity to numerous innovative life science and technology organisations, opening up opportunities for further collaborations with potential partners and researchers based at the Campus.

Dr Chris Torrance, CEO, PhoreMost, said: “Our move to Unity Campus follows a significant year for the Company, including a successful £33M Series B investment round in March 2021. As a team, remaining within the Cambridge biotech cluster is important, to help fuel new strategic collaborations, and support those already in progress. This move brings the whole team together in one site, where previously we were split across two buildings. With further space available at Unity Campus, we are well positioned to continue to advance and expand our drug discovery programmes across high value, but under-served, therapeutic areas.”

Katherine Friend, Director - Investment & Asset Management, Howard Group, added: “The relocation of PhoreMost’s headquarters to Unity Campus exemplifies the specialist network of innovative, agile, science and technology organisations we are establishing here. We have thoroughly enjoyed working with the Phoremost team to tailor their new laboratory and office space within The Works and are excited to welcome them at such a pivotal time in the Company’s development. We look forward to continuing to work collaboratively with PhoreMost as it continues to grow.”

Having completed The Works in 2020, the second phase of Howard Group’s re-development of Unity Campus is now being brought forward. In response to market demand for agile, flexible science space, Phase 2 will consist of three buildings - totalling 95,000 sq ft - all specifically designed to provide high quality accommodation for life science occupiers.  Each building will consist of ground, first and second floor office and laboratory accommodation, with landlord plant provision above. Subject to planning, it is anticipated that Phase 2 will be available from Q1 2023, with units from 10,000 sq ft now available for pre-let. Howard Group welcomes enquiries from potential occupiers wishing to engage at this early stage to enable bespoke requirements to be taken into account.

In addition to Phoremost, current life sciences occupiers at Unity Campus include Aqdot, IONTAS, Liminal Bioscience and Sareum.


About PhoreMost Ltd

PhoreMost has developed a next-generation phenotypic screening platform called SITESEEKER® that can discern the best new targets for future therapy and crucially, how to drug them, which has the potential to significantly increase the diversity and affordability of novel therapeutics for cancer and other unmet diseases. Based on the Company's core proprietary 'Protein Interference' technology, SITESEEKER® systematically unmasks cryptic druggable sites across the entire human genome and directly links them to useful therapeutic functions in a live-cell context. Using this platform, PhoreMost is building a pipeline of novel drug discovery programmes aimed at addressing a range of unmet diseases.  


About Howard Group

Established in 1935 and with headquarters in the centre of Cambridge, Howard Group is a leading regional property investor and developer. The Group also provides growth capital funding, strategic and management support to mid-sized businesses across a diverse range of sectors.

As a family-owned company, our name and our long-standing values run through everything we do. Now in our 86th year, we have built an enduring business by creating, nurturing and valuing lasting relationships. Our professionalism, transparency and commitment to delivery, coupled with a collaborative approach, means that we enjoy strong, long-lasting relationships with our partners.



Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin


Request your free copies HERE




Popular this Month

Top 10 most popular articles this month



Today's Picks



Looking for a Supplier?

Search by company or by product


Company Name:






Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


Media Partners


Exhibitions & Events